益生菌发酵乳对肠易激综合征患者症状及肠道菌群的影响:一项随机、安慰剂对照试验
Effects of probiotic fermented milk on symptoms and intestinal flora in patients with irritable bowel syndrome: a randomized, placebo-controlled trial.
作者信息
Søndergaard Bo, Olsson Johan, Ohlson Kajsa, Svensson Ulla, Bytzer Peter, Ekesbo Rickard
机构信息
Department of Medicine, Glostrup University Hospital, Glostrup, Denmark.
出版信息
Scand J Gastroenterol. 2011 Jun;46(6):663-72. doi: 10.3109/00365521.2011.565066. Epub 2011 Mar 28.
OBJECTIVE
The effect of probiotics on IBS symptoms has been mixed, but remains an intriguing treatment option with appeal to the patient.
MATERIAL AND METHODS
Patients fulfilling the Rome II criteria were randomized double-blind to a daily intake of 500 ml of fermented milk containing at least 5 × 10(7) CFU/ml of Lactobacillus paracasei ssp paracasei F19, Lactobacillus acidophilus La5 and Bifidobacterium lactis Bb12 or an equal volume of acidified milk for 8 weeks. Symptoms were assessed at baseline and weekly using a disease-specific validated symptom rating scale (IBS-SSI). The predefined primary outcome measure was patient reported adequate symptom relief. Adherence to study protocol were assessed by performing stool samples at the of the treatment period.
RESULTS
Eight-one patients were screened. Sixty-four patients were randomized; 18 patients did not complete the study due to protocol violations or withdrew due to lack of effect. Fifty-two patients (13 males) completed the study as per protocol; mean age was 51.3 years (range 29-67). The proportion of patients reporting adequate symptom relief increased in both patient groups, but there was not any statistical difference between the groups. IBS-SSI scores did not differ statistically between the groups at the end of the treatment period, but improved during the study period in both groups.
CONCLUSIONS
During this 8-week trial gastrointestinal symptoms improved. However, there was no difference between treatment with fermented milk containing probiotics or acidified milk. The effect of probiotics on IBS symptoms remains uncertain and further studies are warranted.
目的
益生菌对肠易激综合征(IBS)症状的影响不一,但仍是一种吸引患者的有趣治疗选择。
材料与方法
符合罗马II标准的患者被随机双盲分组,一组每日摄入500毫升含有至少5×10⁷CFU/毫升副干酪乳杆菌亚种副干酪乳杆菌F19、嗜酸乳杆菌La5和双歧杆菌Bb12的发酵乳,另一组摄入等量的酸化乳,为期8周。在基线时及每周使用经过验证的疾病特异性症状评定量表(IBS-SSI)评估症状。预先定义的主要结局指标是患者报告症状得到充分缓解。在治疗期结束时通过采集粪便样本评估对研究方案的依从性。
结果
共筛查81例患者。64例患者被随机分组;18例患者因违反方案未完成研究或因无效而退出。52例患者(13例男性)按方案完成研究;平均年龄51.3岁(范围29 - 67岁)。两组中报告症状得到充分缓解的患者比例均有所增加,但两组之间无统计学差异。治疗期结束时两组的IBS-SSI评分无统计学差异,但两组在研究期间均有所改善。
结论
在这项为期8周的试验中,胃肠道症状有所改善。然而,含益生菌的发酵乳治疗与酸化乳治疗之间无差异。益生菌对IBS症状的影响仍不确定,有必要进一步研究。